Skip to main
MAZE

MAZE Stock Forecast & Price Target

MAZE Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Maze Therapeutics Inc is making significant strides in the development of precision medicines for chronic kidney disease (CKD), particularly with its lead programs MZE829 and MZE782, which have demonstrated compelling efficacy signals in clinical trials. The expected enhancement of the commercial landscape due to improved ICD-10-CM codes, combined with the positive trends in proteinuria reduction and eGFR slope from MZE829's Phase 2 HORIZON trial, supports the likelihood of accelerated regulatory approval. Additionally, the promising pharmacokinetic profile of MZE782, along with its strong efficacy data, positions Maze competitively in the market and justifies an increased projection for market penetration of MZE829, signaling a favorable outlook for the company's stock.

Bears say

Maze Therapeutics Inc faces significant challenges that contribute to a negative outlook on its stock performance. The company is advancing investigational drugs for chronic kidney disease (CKD) but is encountering difficulties in demonstrating robust efficacy signals, with risks related to variable patient responses and concerns about the reliability of surrogate endpoints, which may hinder progress in clinical trials. Additionally, the observed dose-dependent declines in estimated glomerular filtration rate (eGFR) among patients, coupled with the substantial proportion of individuals experiencing inadequate responses to existing treatments, raises concerns about the commercial viability and therapeutic impact of Maze Therapeutics's pipeline products.

MAZE has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Maze Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Maze Therapeutics Inc (MAZE) Forecast

Analysts have given MAZE a Buy based on their latest research and market trends.

According to 8 analysts, MAZE has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Maze Therapeutics Inc (MAZE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.